Clinical Trials on Glycosylated Ferritin in SARS-CoV-2 Infection in Hospitalized COVID-19 Patients in Australia

Total 24 results

University of Melbourne
The George Institute; The University of Queensland; The Peter Doherty Institute... and other collaborators

Recruiting

Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (ASCOT ADAPT)

SARS-CoV-2 Infection (COVID-19)

Australia
Murdoch Childrens Research Institute
Rhinomed Pty Ltd

Completed

Diagnosis of Respiratory Viruses in Children With Rhinoswab Junior

COVID-19 | SARS CoV 2 Infection

Australia
Medical University Innsbruck

Recruiting

Neurological Outcome After SARS-CoV-2 Infection (ATTRACT)

SARS-CoV-2 | Post-acute COVID-19 Syndrome

Austria
Technovalia, Pty Ltd
Chulalongkorn University; Southern Star Research Pty Ltd.; BioNet-Asia

Active, not recruiting

Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults

COVID-19, SARS CoV 2 Infection

Australia
Medical University Innsbruck
Medical University of Graz; Medical University of Vienna

Recruiting

Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2 (HeVacc)

SARS-CoV2 Infection

Austria
Memo Therapeutics AG

Completed

To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19.

SARS-CoV-2 Infection

Australia
NGM Biopharmaceuticals, Inc

Terminated

A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19

SARS-CoV-2 Infection

Australia
Novavax

Completed

Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines (COVID-19)

COVID-19 | SARS CoV 2 Infection

Australia
Gilead Sciences

Approved for marketing

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

SARS-CoV2 Infection

United States, Israel, Belgium, Spain, Australia, Denmark, Italy, Germany, France, Portugal, United Kingdom, Poland, Switzerland, Canada, Austria, Cyprus, Czechia, Estonia, Greece, Hungary, Iceland, Ireland, Lithuania, Netherlands, Romania and more
ACM Biolabs

Completed

Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally.

SARS-CoV-2 Infection

Australia
ModernaTX, Inc.

Recruiting

A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults

SARS-CoV-2

Australia
University of Melbourne
London School of Hygiene and Tropical Medicine; The Alfred; University of Adelaide and other collaborators

Recruiting

Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection

Influenza, Human | SARS-CoV-2 Infection

Australia
University of Melbourne
Southern Star Research Pty Ltd.

Completed

Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults

SARS-CoV-2

Australia
GlaxoSmithKline
CureVac

Active, not recruiting

A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults

SARS-CoV-2

Australia, United States
St. Anna Kinderkrebsforschung

Completed

COVID-19: Infectious Potential of SARS-CoV-2 Intestinal Shedding in Pediatric Patients (INPOSIS) (INPOSIS)

Covid19 | SARS-CoV-2 Infection | Intestinal Infection

Austria
AUVA
Paracelsus Medical University

Completed

Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.

Coronavirus Infection | SARS-CoV 2 | Covid19 | Severe Acute Respiratory Syndrome Coronavirus 2

Austria
Medical University of Vienna

Unknown

Vienna Versus SARS-CoV-2 Virus Study (VIVI)

COVID-19 | SARS-CoV-2

Austria
Medical University Innsbruck

Unknown

Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19

COVID-19 | SARS-CoV 2

Austria
BioNTech SE
Pfizer

Completed

Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age

COVID-19 | SARS-CoV-2 Infection

Australia, New Zealand
Pfizer

Completed

Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age

COVID-19 | SARS-CoV-2 Infection

Australia, New Zealand
AstraZeneca

Active, not recruiting

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (SUPERNOVA)

COVID-19, SARS-CoV-2

United States, Belgium, Canada, France, Spain, Denmark, Thailand, Vietnam, Korea, Republic of, United Kingdom, Malaysia, Israel, Taiwan, Australia, Germany, Poland, Singapore, United Arab Emirates
Medical University Innsbruck
Ludwig-Maximilians - University of Munich; Deutsches Zentrum für Herz-Kreislauf-Forschung...

Completed

Stopping ACE-inhibitors in COVID-19 (ACEI-COVID)

COVID-19 | SARS-CoV-2

Germany, Austria
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

COVID-19 | SARS-CoV-2

Australia, United States, Philippines
University of Chile
Columbia University

Recruiting

The Covid-19 HEalth caRe wOrkErS (HEROES) Study (HEROES)

Depression | Covid-19 | Anxiety | Mental Health Disorder | SARS-CoV-2 | Stress Disorder

United States, Italy, Argentina, Armenia, Australia, Bolivia, Chile, Costa Rica, Czechia, Germany, Guatemala, Lebanon, Mexico, Netherlands, Nigeria, Puerto Rico, Saudi Arabia, Spain, Tunisia, Turkey, Venezuela

Clinical Trials on Glycosylated Ferritin in SARS-CoV-2 Infection in Hospitalized COVID-19 Patients in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations